Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Maravai Lifesciences Holdings, Inc.

NASDAQ: MRVI · Life Sciences · 2 alerts · CIK 1823239

Share price
$7.40Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Maravai Lifesciences Holdings, Inc. filings on SEC EDGAR ↗

4:04 PM ET 10-Q
Financial Results

Maravai Lifesciences Holdings Q3 2026 Results: Net Loss of $13.8M, Loss Narrows

Maravai LifeSciences Holdings, Inc. reported its Q3 2026 financial results, noting significant revenue dependency on CleanCap® for vaccine programs and ongoing risks from organizational changes and workforce reductions. As of October 29, 2026, the company had 149,254,467 Class A and 110,684,080 Class B shares outstanding, while maintaining its status as an accelerated filer.

Key figure
Net loss $13.8M
4:03 PM ET 8-K
Financial Results

Maravai Lifesciences Holdings Financial Results

Maravai LifeSciences reported Q3 2026 total revenue of $45.9 million, a 10% increase year-over-year, driven by strong demand for mRNA products and GMP consumables. The company narrowed its net loss to $24.0 million and raised its full-year 2026 revenue and Adjusted EBITDA guidance based on positive momentum in its TriLink and Cygnus segments.

Term
Q3 2026

“Our third- quarter results build on the momentum we established in the first half of the year. TriLink revenue grew 12% year-over-year led by 28% revenue growth for our mRNA products, while Cygnus delivered its sixth consecutive quarter of year-over-year growth, with revenue up 8%.”

Bernd Brust, CEO of Maravai LifeSciences

“Four Discovery mRNA customers transitioned to clinical-stage GMP this quarter, reinforcing our belief that today’s Discovery success will create tomorrow’s GMP opportunity. Based on our third-quarter performance and our expectations for the fourth quarter, we are raising our full-year revenue and adjusted EBITDA guidance.”

Bernd Brust, CEO of Maravai LifeSciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.